These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 25265335)

  • 1. Characterization of chikungunya virus-like particles.
    Noranate N; Takeda N; Chetanachan P; Sittisaman P; A-Nuegoonpipat A; Anantapreecha S
    PLoS One; 2014; 9(9):e108169. PubMed ID: 25265335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antigenicity and immunogenicity of chikungunya virus-like particles from mosquito cells.
    Tsai SK; Hsu YL; Chiao DJ; Shu PY; Lin HT; Chang SF; Lin HC; Huang SH; Wang CH; Hsiung CC; Lin CC; Wu TY; Kuo SC
    Appl Microbiol Biotechnol; 2023 Jan; 107(1):219-232. PubMed ID: 36434113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression and Characterization of Yeast Derived Chikungunya Virus Like Particles (CHIK-VLPs) and Its Evaluation as a Potential Vaccine Candidate.
    Saraswat S; Athmaram TN; Parida M; Agarwal A; Saha A; Dash PK
    PLoS Negl Trop Dis; 2016 Jul; 10(7):e0004782. PubMed ID: 27399001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bacteriophage Qβ virus-like particles displaying Chikungunya virus B-cell epitopes elicit high-titer E2 protein antibodies but fail to neutralize a Thailand strain of Chikungunya virus.
    Basu R; Zhai L; Rosso B; Tumban E
    Vaccine; 2020 Mar; 38(11):2542-2550. PubMed ID: 32044164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-Chikungunya Virus Monoclonal Antibody That Inhibits Viral Fusion and Release.
    Tumkosit U; Siripanyaphinyo U; Takeda N; Tsuji M; Maeda Y; Ruchusatsawat K; Shioda T; Mizushima H; Chetanachan P; Wongjaroen P; Matsuura Y; Tatsumi M; Tanaka A
    J Virol; 2020 Sep; 94(19):. PubMed ID: 32699087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exposure of epitope residues on the outer face of the chikungunya virus envelope trimer determines antibody neutralizing efficacy.
    Fong RH; Banik SS; Mattia K; Barnes T; Tucker D; Liss N; Lu K; Selvarajah S; Srinivasan S; Mabila M; Miller A; Muench MO; Michault A; Rucker JB; Paes C; Simmons G; Kahle KM; Doranz BJ
    J Virol; 2014 Dec; 88(24):14364-79. PubMed ID: 25275138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chikungunya virus-like particles are more immunogenic in a lethal AG129 mouse model compared to glycoprotein E1 or E2 subunits.
    Metz SW; Martina BE; van den Doel P; Geertsema C; Osterhaus AD; Vlak JM; Pijlman GP
    Vaccine; 2013 Dec; 31(51):6092-6. PubMed ID: 24099875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection.
    García-Arriaza J; Cepeda V; Hallengärd D; Sorzano CÓ; Kümmerer BM; Liljeström P; Esteban M
    J Virol; 2014 Mar; 88(6):3527-47. PubMed ID: 24403588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a pseudotyped-lentiviral-vector-based neutralization assay for chikungunya virus infection.
    Kishishita N; Takeda N; Anuegoonpipat A; Anantapreecha S
    J Clin Microbiol; 2013 May; 51(5):1389-95. PubMed ID: 23408687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [[Virus-like particle-based immunoglobulin M capture enzyme-linked immunosorbent assay for the detection of IgM antibodies against Chikungunya virus].
    Li JD; Zhang QF; Zhang S; Li C; Liu QZ; Liang MF; Li DX
    Bing Du Xue Bao; 2014 Nov; 30(6):599-604. PubMed ID: 25868272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Construction and Evaluation of Recombinant Adenovirus Candidate Vaccines for Chikungunya Virus.
    Cao L; Wang W; Sun W; Zhang J; Han J; Xie C; Ha Z; Xie Y; Zhang H; Jin N; Lu H
    Viruses; 2022 Aug; 14(8):. PubMed ID: 36016401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-Immunization With CHIKV VLP and DNA Vaccines Induces a Promising Humoral Response in Mice.
    Zhao Z; Deng Y; Niu P; Song J; Wang W; Du Y; Huang B; Wang W; Zhang L; Zhao P; Tan W
    Front Immunol; 2021; 12():655743. PubMed ID: 33868299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and evaluation of baculovirus-expressed Chikungunya virus E1 envelope proteins for serodiagnosis of Chikungunya infection.
    Kumar P; Pok KY; Tan LK; Angela C; Leo YS; Ng LC
    J Virol Methods; 2014 Sep; 206():67-75. PubMed ID: 24880071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of chikungunya virus infection in children from India during 2009-2010: A cross sectional observational study.
    Raghavendhar BS; Ray P; Ratagiri VH; Sharma BS; Kabra SK; Lodha R
    J Med Virol; 2016 Jun; 88(6):923-30. PubMed ID: 26581026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enzyme-linked immunosorbent assay using recombinant envelope protein 2 antigen for diagnosis of Chikungunya virus.
    Fumagalli MJ; de Souza WM; Espósito DLA; Silva A; Romeiro MF; Martinez EZ; da Fonseca BAL; Figueiredo LTM
    Virol J; 2018 Jul; 15(1):112. PubMed ID: 30041676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High yield expression and purification of Chikungunya virus E2 recombinant protein and its evaluation for serodiagnosis.
    Verma A; Chandele A; Nayak K; Kaja MK; Arulandu A; Lodha R; Ray P
    J Virol Methods; 2016 Sep; 235():73-79. PubMed ID: 27180040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A chikungunya fever vaccine utilizing an insect-specific virus platform.
    Erasmus JH; Auguste AJ; Kaelber JT; Luo H; Rossi SL; Fenton K; Leal G; Kim DY; Chiu W; Wang T; Frolov I; Nasar F; Weaver SC
    Nat Med; 2017 Feb; 23(2):192-199. PubMed ID: 27991917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A sensitive epitope-blocking ELISA for the detection of Chikungunya virus-specific antibodies in patients.
    Goh LY; Kam YW; Metz SW; Hobson-Peters J; Prow NA; McCarthy S; Smith DW; Pijlman GP; Ng LF; Hall RA
    J Virol Methods; 2015 Sep; 222():55-61. PubMed ID: 26025459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and characterization of monoclonal antibody against non-structural protein-2 of Chikungunya virus and its application.
    Chattopadhyay S; Kumar A; Mamidi P; Nayak TK; Das I; Chhatai J; Basantray I; Bramha U; Maiti PK; Singh S; Suryawanshi AR; Chattopadhyay S
    J Virol Methods; 2014 Apr; 199():86-94. PubMed ID: 24462973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of Immunogenicity and Neutralisation Efficacy of Viral-Vectored Vaccines Against Chikungunya Virus.
    López-Camacho C; Kim YC; Blight J; Lazaro Moreli M; Montoya-Diaz E; Huiskonen JT; Kümmerer BM; Reyes-Sandoval A
    Viruses; 2019 Apr; 11(4):. PubMed ID: 30987160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.